Trial Profile
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Feb 2023
Price :
$35
*
At a glance
- Drugs Fruquintinib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Male breast cancer; Solid tumours
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Hutchison MediPharma; HUTCHMED
- 08 Feb 2023 Planned End Date changed from 21 Apr 2023 to 31 Mar 2023.
- 17 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 17 Nov 2022 Planned End Date changed from 28 Feb 2023 to 21 Apr 2023.